{"DataElement":{"publicId":"7639521","version":"1","preferredName":"Diagnosis Identifier Known Suspected Identifier","preferredDefinition":"The diagnosis, as indicated by the Investigator, best fits in the following selections.","longName":"Kn_Sus_Dx_Idf","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2475359","version":"1","preferredName":"Diagnosis Identifier","preferredDefinition":"The process of identifying a disease by the signs and symptoms._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"2442484v1.0:2222848v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2442484","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"09046428-50E1-6C1D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-01-04","modifiedBy":"ONEDATA","dateModified":"2006-01-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2222848","version":"1","preferredName":"Identifier","preferredDefinition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"C25364","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62113C1-8528-4E73-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER_EVS","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11A4CC33-0704-36E9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-17","endDate":null,"createdBy":"UMLLOADER_CATIES_2","dateCreated":"2006-04-17","modifiedBy":"SBR","dateModified":"2017-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7639511","version":"1","preferredName":"Known Suspected Identifier","preferredDefinition":"Recognized, familiar, or within the scope of knowledge._Believed likely._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"7639511v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"181","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Acute Lymphoblastic Leukemia (ALL)","valueDescription":"Acute lymphoblastic leukemia (ALL)","ValueMeaning":{"publicId":"2580024","version":"1","preferredName":"Acute lymphoblastic leukemia (ALL)","longName":"2580024","preferredDefinition":"Acute lymphoblastic leukemia (ALL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-05A5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-22","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-22","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C11EAE71-F65B-0D50-E053-4EBD850A2DEB","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","deletedIndicator":"No"},{"value":"Mixed Phenotype Acute Leukemia (MPAL)","valueDescription":"Mixed Phenotype Acute Leukemia (MPAL)","ValueMeaning":{"publicId":"7648337","version":"1","preferredName":"Mixed Phenotype Acute Leukemia (MPAL)","longName":"7648337","preferredDefinition":"Mixed Phenotype Acute Leukemia (MPAL)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C11EAE71-F665-0D50-E053-4EBD850A2DEB","latestVersionIndicator":"Yes","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C11EAE71-F67E-0D50-E053-4EBD850A2DEB","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","deletedIndicator":"No"},{"value":"Down Syndrome Acute Myeloid Leukemia (AML)","valueDescription":"Down Syndrome Acute Myeloid Leukemia (AML)","ValueMeaning":{"publicId":"7648338","version":"1","preferredName":"Down Syndrome Acute Myeloid Leukemia (AML)","longName":"7648338","preferredDefinition":"Down Syndrome Acute Myeloid Leukemia (AML)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C11EAE71-F688-0D50-E053-4EBD850A2DEB","latestVersionIndicator":"Yes","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C11EAE71-F6A1-0D50-E053-4EBD850A2DEB","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","deletedIndicator":"No"},{"value":"Treatment-related Acute Myeloid Leukemia","valueDescription":"Treatment-related Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2934528","version":"1","preferredName":"Treatment-related Acute Myeloid Leukemia","longName":"2934528","preferredDefinition":"Treatment-related Acute Myeloid Leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7183CEF2-4949-A86B-E040-BB89AD436AE3","latestVersionIndicator":"Yes","beginDate":"2009-08-19","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-08-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C11EAE71-F6AB-0D50-E053-4EBD850A2DEB","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia (AML)","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C11EAE71-F6BF-0D50-E053-4EBD850A2DEB","beginDate":"2021-04-29","endDate":null,"createdBy":"LEEW","dateCreated":"2021-04-29","modifiedBy":"ONEDATA","dateModified":"2021-04-29","deletedIndicator":"No"},{"value":"de novo or relapsed refractory (including primary refractory) treatment related AML","valueDescription":"de novo or relapsed refractory (including primary refractory) treatment related AML","ValueMeaning":{"publicId":"7639512","version":"1","preferredName":"de novo or relapsed refractory (including primary refractory) treatment related AML","longName":"7639512","preferredDefinition":"de novo or relapsed refractory (including primary refractory) treatment related AML","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D87D-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D896-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"Relapsed refractory (including primary refractory) mixed phenotype acute leukemia","valueDescription":"Relapsed refractory (including primary refractory) mixed phenotype acute leukemia","ValueMeaning":{"publicId":"7639513","version":"1","preferredName":"Relapsed refractory (including primary refractory) mixed phenotype acute leukemia","longName":"7639513","preferredDefinition":"Relapsed refractory (including primary refractory) mixed phenotype acute leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D8A0-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":"2023.9.6 Alt VM added per ticket request CADSR0002816. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D8B9-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"ALL with first or greater relapse of T-ALL, involving KMT2Ar","valueDescription":"ALL with first or greater relapse of T-ALL, involving KMT2Ar","ValueMeaning":{"publicId":"7639514","version":"1","preferredName":"ALL with first or greater relapse of T-ALL, involving KMT2Ar","longName":"7639514","preferredDefinition":"ALL with first or greater relapse of T-ALL, involving KMT2Ar","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D8C3-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D8DC-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"ALL with first or greater relapse of T-ALL excluding KMT2Ar","valueDescription":"ALL with first or greater relapse of T-ALL excluding KMT2Ar","ValueMeaning":{"publicId":"7639515","version":"1","preferredName":"ALL with first or greater relapse of T-ALL excluding KMT2Ar","longName":"7639515","preferredDefinition":"ALL with first or greater relapse of T-ALL excluding KMT2Ar","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D8E6-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D8FF-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"ALL with first or greater medullary relapse of B-ALL, involving KMT2Ar","valueDescription":"ALL with first or greater medullary relapse of B-ALL, involving KMT2Ar","ValueMeaning":{"publicId":"7639516","version":"1","preferredName":"ALL with first or greater medullary relapse of B-ALL, involving KMT2Ar","longName":"7639516","preferredDefinition":"ALL with first or greater medullary relapse of B-ALL, involving KMT2Ar","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D909-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D922-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"ALL with second or greater medullary relapse of B-ALL, excluding KMT2Ar","valueDescription":"ALL with second or greater medullary relapse of B-ALL, excluding KMT2Ar","ValueMeaning":{"publicId":"7639517","version":"1","preferredName":"ALL with second or greater medullary relapse of B-ALL, excluding KMT2Ar","longName":"7639517","preferredDefinition":"ALL with second or greater medullary relapse of B-ALL, excluding KMT2Ar","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D92C-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D945-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"Relapsed refractory (including primary refractory) AML with Down syndrome","valueDescription":"Relapsed refractory (including primary refractory) AML with Down syndrome","ValueMeaning":{"publicId":"7639518","version":"1","preferredName":"Relapsed refractory (including primary refractory) AML with Down syndrome","longName":"7639518","preferredDefinition":"Relapsed refractory (including primary refractory) AML with Down syndrome","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D94F-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D968-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"Relapsed refractory (including primary refractory) AML","valueDescription":"Relapsed refractory (including primary refractory) AML","ValueMeaning":{"publicId":"7639519","version":"1","preferredName":"Relapsed refractory (including primary refractory) AML","longName":"7639519","preferredDefinition":"Relapsed refractory (including primary refractory) AML","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D972-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C0812025-D98B-7D97-E053-4EBD850A51C2","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"ONEDATA","dateModified":"2021-04-21","deletedIndicator":"No"},{"value":"ALL with first or greater T-ALL medullary relapse with KMT2Ar","valueDescription":"ALL with first or greater T-ALL medullary relapse with KMT2Ar","ValueMeaning":{"publicId":"7736577","version":"1","preferredName":"ALL with first or greater T-ALL medullary relapse with KMT2Ar","longName":"7736577","preferredDefinition":"ALL with first or greater T-ALL medullary relapse with KMT2Ar","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F12D6A-EB53-7CAB-E053-4EBD850A87AB","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"LEEW","dateCreated":"2021-07-12","modifiedBy":"ONEDATA","dateModified":"2021-07-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6F12D6A-EB6C-7CAB-E053-4EBD850A87AB","beginDate":"2021-07-12","endDate":null,"createdBy":"LEEW","dateCreated":"2021-07-12","modifiedBy":"ONEDATA","dateModified":"2021-07-12","deletedIndicator":"No"},{"value":"ALL with first or greater T-ALL medullary relapse without KMT2Ar","valueDescription":"ALL with first or greater T-ALL medullary relapse without KMT2Ar","ValueMeaning":{"publicId":"7736578","version":"1","preferredName":"ALL with first or greater T-ALL medullary relapse without KMT2Ar","longName":"7736578","preferredDefinition":"ALL with first or greater T-ALL medullary relapse without KMT2Ar","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6F12D6A-EB76-7CAB-E053-4EBD850A87AB","latestVersionIndicator":"Yes","beginDate":"2021-07-12","endDate":null,"createdBy":"LEEW","dateCreated":"2021-07-12","modifiedBy":"ONEDATA","dateModified":"2021-07-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C6F12D6A-EB8F-7CAB-E053-4EBD850A87AB","beginDate":"2021-07-12","endDate":null,"createdBy":"LEEW","dateCreated":"2021-07-12","modifiedBy":"ONEDATA","dateModified":"2021-07-12","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome (MDS)","valueDescription":null,"ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B21FF1-EE39-167B-E063-731AD00A1DCD","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"Juvenile Myelomonocytic Leukemia (JMML)","valueDescription":null,"ValueMeaning":{"publicId":"2838584","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2838584","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5942-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B21FF1-EE3A-167B-E063-731AD00A1DCD","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"de novo Myelodysplastic Syndrome (MDS)","valueDescription":null,"ValueMeaning":{"publicId":"14461936","version":"1","preferredName":"de novo Myelodysplastic Syndrome","longName":"14461936v1.00","preferredDefinition":"A primary myelodysplastic syndrome not associated with prior radiation or chemotherapy treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"de novo Myelodysplastic Syndrome","conceptCode":"C8253","definition":"A primary myelodysplastic syndrome not associated with prior radiation or chemotherapy treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B49245-C7AC-18EB-E063-731AD00ABBE2","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B49245-C7AF-18EB-E063-731AD00ABBE2","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"de novo treatment-related AML (t-AML)","valueDescription":null,"ValueMeaning":{"publicId":"14461937","version":"1","preferredName":"de novo treatment-related AML (t-AML)","longName":"14461937v1.00","preferredDefinition":"de novo treatment-related AML (t-AML)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B4AE06-E541-1DA2-E063-731AD00A26F5","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B4AE06-E547-1DA2-E063-731AD00A26F5","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"de novo treatment-related Myelodysplastic Syndrome (t-MDS)","valueDescription":null,"ValueMeaning":{"publicId":"14461938","version":"1","preferredName":"de novo treatment-related Myelodysplastic Syndrome (t-MDS)","longName":"14461938v1.00","preferredDefinition":"de novo treatment-related Myelodysplastic Syndrome (t-MDS)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B4AE06-E542-1DA2-E063-731AD00A26F5","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B4AE06-E548-1DA2-E063-731AD00A26F5","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"Relapsed refractory (including primary refractory) treatment-related Myelodysplastic Syndrome (t-MDS)","valueDescription":null,"ValueMeaning":{"publicId":"14461939","version":"1","preferredName":"Relapsed refractory (including primary refractory) treatment-related Myelodysplastic Syndrome (t-MDS)","longName":"14461939v1.00","preferredDefinition":"Relapsed refractory (including primary refractory) treatment-related Myelodysplastic Syndrome (t-MDS)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B4AE06-E543-1DA2-E063-731AD00A26F5","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B4AE06-E549-1DA2-E063-731AD00A26F5","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"Relapsed refractory (including primary refractory) Myelodysplastic Syndrome (MDS)","valueDescription":null,"ValueMeaning":{"publicId":"14461940","version":"1","preferredName":"Relapsed refractory (including primary refractory) Myelodysplastic Syndrome (MDS)","longName":"14461940v1.00","preferredDefinition":"Relapsed refractory (including primary refractory) Myelodysplastic Syndrome (MDS)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B4AE06-E544-1DA2-E063-731AD00A26F5","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B4AE06-E54A-1DA2-E063-731AD00A26F5","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"de novo Juvenile Myelomonocytic Leukemia (JMML)","valueDescription":null,"ValueMeaning":{"publicId":"14461941","version":"1","preferredName":"de novo Juvenile Myelomonocytic Leukemia (JMML)","longName":"14461941v1.00","preferredDefinition":"de novo Juvenile Myelomonocytic Leukemia (JMML)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B4AE06-E545-1DA2-E063-731AD00A26F5","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B4AE06-E54B-1DA2-E063-731AD00A26F5","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"},{"value":"Relapsed refractory (including primary refractory) Juvenile Myelomonocytic Leukemia (JMML)","valueDescription":null,"ValueMeaning":{"publicId":"14461942","version":"1","preferredName":"Relapsed refractory (including primary refractory) Juvenile Myelomonocytic Leukemia (JMML)","longName":"14461942v1.00","preferredDefinition":"Relapsed refractory (including primary refractory) Juvenile Myelomonocytic Leukemia (JMML)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"04B4AE06-E546-1DA2-E063-731AD00A26F5","latestVersionIndicator":"Yes","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04B4AE06-E54C-1DA2-E063-731AD00A26F5","beginDate":"2023-09-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7639062","version":"1","preferredName":"Known Suspected Identifier","preferredDefinition":"Recognized, familiar, or within the scope of knowledge.:Believed likely.:One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","longName":"C80137:C71458:C25364","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Known","conceptCode":"C80137","definition":"Recognized, familiar, or within the scope of knowledge.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Suspected","conceptCode":"C71458","definition":"Believed likely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Identifier","conceptCode":"C25364","definition":"One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C06B9402-A67B-5277-E053-4EBD850A50DC","latestVersionIndicator":"Yes","beginDate":"2021-04-20","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-20","modifiedBy":"ONEDATA","dateModified":"2021-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0812025-D867-7D97-E053-4EBD850A51C2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":"APAL2020SC","administrativeNotes":"2023.9.6 PVs added per ticket request CADSR0002816. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"What is the known or suspecte","type":"Preferred Question Text","description":"What is the known or suspected diagnosis?","url":null,"context":"COG"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"What is the patient's diagnosis?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Diagnosis:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C080D207-7585-791B-E053-4EBD850A6CE2","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"BROWNTY","dateCreated":"2021-04-21","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":"APAL2020SC","administrativeNotes":"2023.9.6 QT added per ticket request CADSR0002816. ak","unresolvedIssues":null,"deletedIndicator":"No"}}